News Detail

Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences

Mon, 03 Jan 2022

Company to Conduct Virtual One-on-One Meetings During Biotech Showcase

Berwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will present at Biotech Showcase 2022 Virtual Conference taking place January 10-12, 2022, and the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13, 2022. Maria L. Maccecchini, Ph.D., Founder, President & Chief Executive Officer, will present an overview of Annovis.

Details can be found below:

Event: Biotech Showcase
Date: January 10-12, 2022
Location: Virtual
Event Website: informaconnect.com/biotech-showcase

Event: H.C. Wainwright Bioconnect Virtual Conference
Date: January 10-13, 2022
Location: Virtual
Event Website: https://hcwevents.com/bioconnect/

Dr. Maccecchini and the Company's business development team will participate in virtual one-on-one meetings with registered Biotech Showcase investors. All interested parties can schedule one-on-one meetings through the PartneringONE platform or through Annovis Bio's investor relations firm listed at the bottom of this release.

About Annovis Bio, Inc.

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as motor function in PD.

For more information on Annovis Bio, please visit the company's website www.annovisbio.com and follow us on LinkedIn, and Twitter.

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified using words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

###

Media and Investor Contact:
Nic Johnson
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/108897

Back to Top